JAK inhibitors and VTE risk: how concerned should we be?

Janus kinase (JAK) inhibitors have become standard treatment for patients with rheumatoid arthritis who do not respond well to other DMARDs. Concerns have been raised over an increased risk of venous thromboembolism with JAK inhibitors, tempering enthusiasm for their use in the clinic, but are these concerns justified?

Automated summary

JAK inhibitors are now a standard treatment for rheumatoid arthritis patients, but concerns about an increased risk of venous thromboembolism have tempered enthusiasm for their use in clinical settings.